Metabolic RNAi Focus Arrowhead is actively advancing RNAi therapies for obesity and metabolic liver disease, including ARO-INHBE and PNPLA3 targeting programs such as plozasiran for triglyceride lowering. This creates opportunities for collaboration with pharma companies seeking liver-targeted RNAi assets or co development arrangements to accelerate metabolic disease candidates.

Licensing Momentum Arrowhead has actively monetized its pipeline through asset sales and exclusive licensing, notably licensing ARO-PNPLA3 to Madrigal. This demonstrates a willingness to out-license programs or co develop with partners, offering potential entry points for external companies to access clinical stage RNAi assets or collaborate on stage appropriate programs.

Clinical Momentum Public presentations at Jefferies Global Healthcare Conference 2026 and EASL 2026 underscore ongoing data readouts in obesity and MASH programs. This signals upcoming milestones to leverage in partnerships, including data-driven collaborations, joint trials, or sponsored research in obesity, MASH, and triglyceride management.

Platform Capabilities The company operates a scalable research and operations platform supported by tools such as DNAnexus, Procore, LogMeIn, Agiloft, Greenhouse, and ImageJ. This raises opportunities to offer data management, program management, and CRO services as part of a collaboration or licensing deal with Arrowhead, enabling faster discovery and development.

Metabolic Market Position Arrowhead's focus on metabolic diseases creates a target for pharma seeking RNAi driven approaches in obesity, NAFLD/MASH, and triglyceride related indications. Potential sales angles include licensing RNAi assets, partnering on joint development, or leveraging Arrowhead's platform to accelerate metabolic disease programs.